The government of the Maldives has announced the Covid-19 vaccination to begin on February 1.
A government official speaking to Ras Online has confirmed that the Covid-19 vaccination will begin in Male’, Addu, and Kulhudhuffushi. The government official said that the Covishield vaccine donated by the Indian government has already been dispatched to the regional hospitals to commence the vaccination. As per the information received, the vaccines were dispatched with the support of Maldives Military personnel.
The 100,000 doses of the Covishield vaccine manufactured by the Serum Institute of India arrived in the Maldives on January 20. Covishield is based on the Oxford-AstraZeneca vaccine, co-developed by the Oxford University and AstraZeneca to combat Covid-19.
The Covishield vaccine was authorized for restricted emergency use in the Maldives by the Maldives Food and Drug Authority (MFDA) on January 28. The statement released by MFDA reads that the emergency use of the Covishield vaccine is approved after technical considerations from the National Pharmaceutical Board.
MFDA also stated that the Covishield vaccine will not be administered to pregnant women, and the vaccine will only be administered to individuals above 18 years of age.
According to the global media, Bangladesh, Pakistan, Sri Lanka, Nepal, Myanmar, and Brazil has already begun vaccinating using the Covishield vaccine. As per the currently available data, the effectiveness rate of the Covishield vaccine is 70-90%.
A government official speaking to Ras Online has confirmed that the Covid-19 vaccination will begin in Male’, Addu, and Kulhudhuffushi. The government official said that the Covishield vaccine donated by the Indian government has already been dispatched to the regional hospitals to commence the vaccination. As per the information received, the vaccines were dispatched with the support of Maldives Military personnel.
The 100,000 doses of the Covishield vaccine manufactured by the Serum Institute of India arrived in the Maldives on January 20. Covishield is based on the Oxford-AstraZeneca vaccine, co-developed by the Oxford University and AstraZeneca to combat Covid-19.
The Covishield vaccine was authorized for restricted emergency use in the Maldives by the Maldives Food and Drug Authority (MFDA) on January 28. The statement released by MFDA reads that the emergency use of the Covishield vaccine is approved after technical considerations from the National Pharmaceutical Board.
MFDA also stated that the Covishield vaccine will not be administered to pregnant women, and the vaccine will only be administered to individuals above 18 years of age.
According to the global media, Bangladesh, Pakistan, Sri Lanka, Nepal, Myanmar, and Brazil has already begun vaccinating using the Covishield vaccine. As per the currently available data, the effectiveness rate of the Covishield vaccine is 70-90%.
